CN103119064B - Fab糖基化抗体 - Google Patents

Fab糖基化抗体 Download PDF

Info

Publication number
CN103119064B
CN103119064B CN201180039635.7A CN201180039635A CN103119064B CN 103119064 B CN103119064 B CN 103119064B CN 201180039635 A CN201180039635 A CN 201180039635A CN 103119064 B CN103119064 B CN 103119064B
Authority
CN
China
Prior art keywords
antibody
derivative
composition
amino acid
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180039635.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103119064A (zh
Inventor
S·戈莱茨
A·丹尼尔奇克
L·施特克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Publication of CN103119064A publication Critical patent/CN103119064A/zh
Application granted granted Critical
Publication of CN103119064B publication Critical patent/CN103119064B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180039635.7A 2010-08-10 2011-08-10 Fab糖基化抗体 Active CN103119064B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2010004878 2010-08-10
EPPCT/EP2010/004878 2010-08-10
PCT/EP2011/063791 WO2012020065A1 (en) 2010-08-10 2011-08-10 Fab-glycosylated antibodies

Publications (2)

Publication Number Publication Date
CN103119064A CN103119064A (zh) 2013-05-22
CN103119064B true CN103119064B (zh) 2018-09-04

Family

ID=44674756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180039635.7A Active CN103119064B (zh) 2010-08-10 2011-08-10 Fab糖基化抗体

Country Status (12)

Country Link
US (1) US9359439B2 (https=)
EP (1) EP2603528B1 (https=)
JP (2) JP6334166B2 (https=)
CN (1) CN103119064B (https=)
AU (1) AU2011288464B2 (https=)
BR (1) BR112013003095B1 (https=)
CA (1) CA2805984C (https=)
DK (1) DK2603528T3 (https=)
ES (1) ES2605304T3 (https=)
PL (1) PL2603528T3 (https=)
PT (1) PT2603528T (https=)
WO (1) WO2012020065A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CA2908819A1 (en) * 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
JP6214790B2 (ja) * 2014-09-16 2017-10-18 イース チャーム リミテッド 抗ｅｇｆｒ抗体および同抗体の使用法
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
IL268959B2 (en) 2017-02-28 2025-01-01 Seagen Inc Cystine-mutated antibodies, compositions containing them and uses thereof
CA3082231A1 (en) * 2017-11-09 2019-05-16 National Research Council Of Canada Antibody glycoconjugates and methods of production and use
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
MX2023003304A (es) * 2020-09-21 2023-05-09 Systimmune Inc Complejo de union de egfr y metodo de fabricacion y uso del mismo.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016455A2 (en) * 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
US20060051353A1 (en) * 2004-05-14 2006-03-09 Jean-Frederic Colombel Methods and compositions to evaluate antibody treatment response
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PT1896071E (pt) 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20090181016A1 (en) * 2005-11-30 2009-07-16 University Of Southern California FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
JP5628790B2 (ja) * 2008-04-07 2014-11-19 バイエル・ヘルスケア・エルエルシー 糖タンパク質の組換え生産の方法
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US9051370B2 (en) * 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016455A2 (en) * 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments，;Leung S;《J Immunol.》;19950601;第154卷(第11期);5919-5926 *
Isothiocyanate-trigalactose: application for antibody-targeted delivery of diagnostic and therapeutic agents，;Rosebrough SF;《Cancer Biother Radiopharm. 》;20001031;第15卷(第5期);507-515 *
Modulation of antibody pharmacokinetics by chemical polysialylation;Constantinou A;《Bioconjug Chem.》;20080229;第19卷(第3期);643-650 *
Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells;Barry Byrne;《Drug Discovery Today》;20070430;第12卷(第7–8期);Pages 319–326 *

Also Published As

Publication number Publication date
AU2011288464B2 (en) 2015-10-29
AU2011288464A1 (en) 2013-02-14
BR112013003095B1 (pt) 2023-03-28
US20130209458A1 (en) 2013-08-15
PT2603528T (pt) 2016-12-01
BR112013003095A2 (pt) 2016-07-05
CA2805984A1 (en) 2012-02-16
CN103119064A (zh) 2013-05-22
JP2016185169A (ja) 2016-10-27
JP6334166B2 (ja) 2018-05-30
CA2805984C (en) 2021-05-25
US9359439B2 (en) 2016-06-07
EP2603528B1 (en) 2016-10-12
PL2603528T3 (pl) 2017-07-31
ES2605304T3 (es) 2017-03-13
WO2012020065A1 (en) 2012-02-16
JP2013535970A (ja) 2013-09-19
DK2603528T3 (en) 2016-11-28
EP2603528A1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
CN103119064B (zh) Fab糖基化抗体
JP7823114B2 (ja) 抗ｍｕｃ１抗体－薬物コンジュゲート
JP7390414B2 (ja) 糖類工学による部位特異的抗体－薬物コンジュゲーション
JP6670248B2 (ja) 抗ｃｄ３８抗体との併用療法
CN106471010A (zh) 靶向模块的位点特异性糖工程化
CN105229030A (zh) 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
CN120187759A (zh) 抗gucy2c抗体及其用途
CN104394887A (zh) 采用具有低岩藻糖化的抗her2抗体的新治疗性疗法
KR20140130455A (ko) Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
HK40113788A (zh) 抗cd39抗体及其用途
HK40041660A (en) Anti-muc1 antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant